Rick Guidotti, founder of the not-for-profit organization Positive Exposure, says his message for dermatologists is simple: See patients as people first.
Castle Creek Pharmaceuticals announced in June 2017 that the first patient had enrolled in its phase 2/3 study assessing the safety and efficacy of its pipeline diacerein 1% ointment to treat epidermolysis bullosa simplex.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%